[May 25, 2016]

DPP IV Inhibitors - Global Strategic Business Report - Key Players are Novartis AG, AstraZeneca & Eli Lilly and Company - Research and Markets

Research and Markets has announced the addition of the "DPP IV Inhibitors - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 022. The report profiles 23 companies including many key and niche players such as:

• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co, Inc.
• Mitsubishi (News - Alert) Tanabe Pharma Corporation

Key Topics Covered:

1. INDUSTRY OVERVIEW

2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS

3. DIABETES INCIDENCE AND PREVALENCE

4. DPP-IV INHIBITORS

5. PRODUCT APPROVALS/INTRODUCTIONS

6. RECENT INDUSTRY ACTIVITY

7. FOCUS ON (News - Alert) SELECT GLOBAL PLAYERS

• AstraZeneca Plc.
  
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
  
• Merck & Co, Inc.
  
• Mitsubishi Tanabe Pharma Corporation
  
• Novartis AG
  
• Takeda Pharmaceutical Company Limited
  

8. GLOBAL MARKET PERSPECTIVE

For more information visit http://www.researchandmarkets.com/research/x7m2xx/dpp_iv_inhibitors

View source version on businesswire.com: http://www.businesswire.com/news/home/20160525006416/en/

[ Back To TMCnet.com's Homepage ]